|
|
|
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Exhibit No.
|
Description
|
|
Press release dated July 24, 2023
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
INFINITY PHARMACEUTICALS, INC.
|
|
|
|
|
Date: July 24, 2023
|
By:
|
/s/ Seth A. Tasker
|
|
|
Seth A. Tasker
|
|
|
Chief Business Officer
|
Document and Entity Information |
Jul. 23, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 23, 2023 |
Entity File Number | 000-31141 |
Entity Registrant Name | Infinity Pharmaceuticals, Inc. |
Entity Central Index Key | 0001113148 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 33-0655706 |
Entity Address, Address Line One | 1100 Massachusetts Avenue |
Entity Address, Address Line Two | Floor 4 |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02138 |
City Area Code | 617 |
Local Phone Number | 453-1000 |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | INFI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
RHUE-%W='>.UOI#[7!..I2TQ37#U"PKY2QU^/9O5[I.;@6JA0D!XNK G9Y??G-PSL9I-F80-^8) 9<;@\N"@:A!
MDI10:YN_^^9 )B')!X*4(8&$#JNH@'2#G$ Q]0SS)=F8#2$&G66<_KD8)6E.
MMJMWP"]_U_C:$IT8T?E(+ZE1GT(
ME9]*AW_/WL6+E:U5/H2^TL^^)UMR+JYDABGC_%9>P@T<:E-7,P+3,#V'^V8@
M#(,R1FG@NF*-M,Y^/PYE#&.0LP$#@0G$.),\^J]F)%Z?)H$\(WD^0!?M%]FB0] ;<1&&=2IGM9(%,^)
M.<^+JQ1/GN[/OU2E>SFO)E!"8!@ P+5(E;16(^7)Z''1UM;"V&M*]<.4&:B5
M) 4/0:U\7>1@F7O%PE,OX77=%KJ4NY:C4\ C6
M NH;E&N,/? 0PX\FT'/4@D]3X'99FJG)6E2O"?3"UJ>9.)M:NZCY)M%O$GVW
M1)^E BTTGC=1^V#1.4Q/PW A$C(I=4+;L'PCT$Q;6*[F^([F"=SL98IPC?,U
M/[)D XI;00W']]IL:O*6ONV_*P1C+6$O&KR)^YNX/TC<^UDV%FFST-N:9=F<
M!XQJEJE[S'5 3]4JN_3V$-D3NVQ/V=..6;KK21:CVQ2ZO!V]KPXO#^+0_.=_=_>M"
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739B3+N>IR++RSV<9"UK?'*#9GA=:U'>%
M98)M<&U=9XYF,JX%OBW62+;L4R ..699QH+!.!,YQ%O=:Q&/ESRKG=4YH56@
MZO6 UP\"ZKJ^X7#-=#S/I
-I%&@7-0]HJ&+'$I=9$"6@K78P7CX2?CIFZ93H>G%; )Z1ONOT
M] Z@N3IB2&K'@="Y<'5=>U\U5Z_T/1XQ0F56EO8JBZL*W^V0X\-^.="L_TH
M[AP&VLT[ 05+C@7CR0W\2:_ 4;L8^_? BVT8.'9)!$A);M!+R\9^)KE$= [
M(62ST6:]S@=5>DCY=J#%P4+-&$UU?18QQ91ER^T:#LI/L_KS+@L#@48#S Y
M#E'Q57E "_P"&"Y3
#$&,K0,:-4(SH09=